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ABSTRACT
There is growing national and international concern 
about the drug regulatory system in India. Parliamentary 
reports have highlighted the presence of high numbers of 
unapproved medicines and irrational combinations of both 
approved and unapproved drugs in the Indian market-
place. Fixed-dose combinations (FDCs) are a peculiar 
feature of the Indian pharmaceutical landscape. Although 
metformin is a first-line treatment, FDCs for diabetes 
in India account for two-thirds of all diabetes medicine 
sales, and some have not been approved by the Central 
Drugs Standard Control Organization (CDSCO). This study 
examines the basis of efficacy and safety of top-selling 
metformin FDCs in India against four WHO criteria from 
clinical trials guidelines for the approval of FDCs. Data 
from a commercial drug sales database (PharmaTrac) 
were combined with searches through published literature, 
clinical trial registries, and published and unpublished 
trial websites of metformin FDCs in adults with type 2 
diabetes mellitus. Five metformin FDCs in India from 
November 2011 to October 2012 accounted for 80% of 
all metformin FDC sales by value and volume. Although all 
five had obtained CDSCO approval, three had been sold 
and marketed prior to receiving this approval. Evaluation of 
published and unpublished clinical trials of these five FDCs 
found none provided robust evidence of safety and efficacy 
for the treatment of type 2 diabetes. Recommendations 
are made for publishing evidence that underpins drug 
approvals, marketing bans, greater transparency through 
updated clinical trials databases and legislative reform in 
order to prevent irrational FDCs from entering the market.
InTRoduCTIon
Clinical trials are a crucial step in the develop-
ment of new medicines. They are required by 
national drug regulatory agencies to ensure 
medicines are safe and effective for use in a 
human population. Every country is respon-
sible for maintaining a stringent system to 
control the distribution of medicines within 
their borders. Typically, this requires the 
successful completion and adequate presenta-
tion of results from phase I through phase III 
clinical trials, from preliminary safety data 
to the analysis of safety and efficacy results 
from extensive human trials. The US Food 
and Drug Administration (FDA) approves 
approximately 40 new medicines for the 
US market each year through this process.1 
Drug approval packages for new drugs, which 
include a full review of submitted materials 
for approved drugs, are available through the 
FDA’s website. India approves more than 100 
new medicines a year but does not publish 
data on submitted applications or summa-
ries of approved medicines, and concerns 
have been raised about the safety and efficacy 
around medicine approvals in the absence of 
appropriate clinical trials.2–5 
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Key questions 
What is already known about this topic?
 ► Although metformin is a first-line treatment for 
diabetes, fixed-dose combinations (FDCs) in India 
account for the majority of diabetes medicine sales.
 ► The five top-selling FDCs account for 500 brands; 
multinational corporations manufacture all five 
FDCs.
 ► Different dosages of three of the five top-selling 
metformin FDCs were banned by the government 
in March 2016 in its ban of 344 irrational FDCs, but 
the ban was overturned by the Delhi High Court in 
December 2016. The government is challenging 
this in the Supreme Court of India.
What are the new findings?
 ► A review of both published and unpublished 
clinical trials for the five top-selling metformin 
FDCs in India found only one study evaluating the 
efficacy and safety of a metformin FDC versus 
concomitant use of the component drugs as single-
drug formulations; it was underpowered and of 
poor quality.
 ► None of the 25 clinical trials for the five top-selling 
FDCs met all four selected criteria from WHO 
guidelines for the conduct of trials and approval of 
FDC medicines.
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Figure 1 Timeline of important events concerning the five top-selling fixed-dose combinations in India. CDSCO, Central 
Drugs Standard Control Organization; US FDA, US Food and Drug Administration. 
Key questions 
Recommendations for policy
 ► The safety and efficacy considered by the Central Drugs Standard 
Control Organization in approving the five top-selling metformin 
FDCs for the treatment of type 2 diabetes mellitus in India should 
be published immediately. If the evidence does not extend beyond 
the trials reviewed in this paper, those FDCs should be banned 
immediately. If that evidence includes the results of trials not 
reviewed in this paper, but those trials do not meet the WHO 
standards used here for evaluation, those FDCs should be banned.
 ► Clinical trial databases should be constantly updated with both 
protocols and outcomes in order to improve transparency of trial 
data; evidence underpinning drug approvals should be published.
 ► Legislation on clinical trial and data submission requirements for 
FDCs should be revised and aligned with WHO recommendations 
in order to prevent irrational FDCs from entering the market and to 
improve transparency.
 ► The government’s March 2016 ban on FDCs should be reinstated 
and a review of FDCs mandated by the Indian Parliament.
Over 60 million people have been diagnosed with 
type 2 diabetes mellitus in India, which has been 
described as ‘the diabetes capital of the world’.6 Given 
the constant monitoring and rapid adjustment of treat-
ment regimens required to maintain adequate glycaemic 
control, metformin fixed-dose combinations (FDCs) 
are not recommended by national or international 
treatment guidelines. Nevertheless, the Central Drugs 
Standard Control Organization (CDSCO), India’s 
drug regulator, has given approval for 52 FDC formu-
lations for type 2 diabetes, which in turn has given rise 
to more than 500 marketed brands of metformin FDCs. 
In contrast, only two metformin FDCs are approved in 
the USA, one in Australia, and none in either the UK or 
Canada (figure 1).3 4 Twenty-seven metformin FDCs were 
included in the Indian government’s ban of 344 unap-
proved FDCs in March 2016 as having ‘no therapeutic 
justification’ following consideration of nearly 6000 unap-
proved FDCs by an expert committee (see online supple-
mentary table 1).2 The ban was lifted in December 2016 
by the Delhi High Court, but an appeal to the Supreme 
Court is pending.7
One of the primary arguments for prescribing FDCs 
for treatment of type 2 diabetes is improved adherence 
to treatment due to convenience.8 9 While some studies 
suggest FDCs are associated with better adherence than 
concomitant single-drug formulations (SDFs), they 
should only be considered when the patient has been 
stable on a regimen of concomitant SDFs for an extended 
period of time.10–13 Glucose levels fluctuate and treatment 
adjustments are often needed, but such adjustments are 
particularly difficult when using FDCs because doses are 
fixed. Regardless, the convenience of FDCs should not 
trump efficacy.
The availability of irrational or inadequately tested 
medicines puts the safety of the public at risk. It is 
important to ensure that those medicines that are avail-
able on the market have been approved after examina-
tion for safety and efficacy through the implementation 
of appropriately designed and analysed clinical trials. 
This work is an evaluation of the clinical evidence on 
the safety and efficacy of the most common metformin 
FDCs sold for treating type 2 diabetes in India.
GATHeRInG THe leGAl evIdenCe
Indian rules
Drugs in India are regulated by the Drugs and Cosmetics 
Act 1940 and the Drugs and Cosmetics Rules 1945, both 
of which have been amended many times. Imports and 
marketing of new drugs are controlled nationally by 
CDSCO, while manufacture, distribution and sale of drugs 
are the responsibility of the States. ‘New drugs’ as a cate-
gory of ‘drugs’ was first introduced into the Rules in 1952, 
and FDCs were expressly mentioned as a specific subcate-
gory of new drugs in 1988. Part X-A and Schedule Y of the 
Rules—initially inserted in 1988 and significantly revised 
in 2005—set the requirements for manufacturing and 
importing new drugs, including FDCs, for the purposes 
of conducting clinical trials or marketing (table 1).14 
CDSCO must give permission before manufacture and 
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Table 1 Extracts from the opening paragraphs of Schedule Y in 1988 and in 2005, comparing the provisions on phase II, III 
and IV trials as they relate to numbers of trial subjects and centres14
Trial phase 1988 Schedule Y 2005 Schedule Y
Phase II ‘Normally 10–12 patients should be studied at 
each dose level. These studies are usually limited 
to 3–4 centres…’
‘Studies in Phase II should be conducted in a group of 
patients who are selected by relatively narrow criteria 
leading to a relatively homogeneous population. These 
studies should be closely monitored… If the application 
is for conduct of clinical trials as a part of multi-national 
clinical development of the drug, the number of sites and the 
patients as well as the justification for undertaking such trials 
in India shall be provided to the Licensing Authority’.
Phase III ‘If the drug is already approved/marketed in 
other countries, phase III data should generally 
be obtained on at least 100 patients distributed 
over 3–4 centres primarily to confirm the 
efficacy and safety of the drug in Indian patients 
when used as recommended in the product 
monograph for the claims made. If the drug is 
a new drug substance discovered in India, and 
not marketed in any other country, phase III 
data should be obtained on at least 500 patients 
distributed over 10–15 centres’.
‘(iii) For new drugs approved outside India, Phase III studies 
need to be carried out primarily to generate evidence of 
efficacy and safety of the drug in Indian patients when 
used as recommended in the prescribing information. 
Prior to conduct of Phase III studies in Indian subjects, 
Licensing Authority may require pharmacokinetic studies 
to be undertaken to verify that the data generated in Indian 
population is in conformity with the data already generated 
abroad.
(iv) If the application is for the conduct of clinical trials as a 
part of multi-national clinical development of the drug, the 
number of sites and patients as well as the justification for 
undertaking such trials in India should be provided to the 
Licensing Authority along with the application’.
Phase IV* ‘In addition, data on adverse drug reactions 
observed during clinical use of the drug should 
be collected in 1000–2000 patients…’ 
‘Post Marketing trials are studies (other than routine 
surveillance) performed after drug approval and related 
to the approved indication(s). These trials go beyond the 
prior demonstration of the drug’s safety, efficacy and dose 
definition. These trials may not be considered necessary at 
the time of new drug approval but may be required by the 
Licensing Authority for optimising the drug’s use. They may 
be of any type but should have valid scientific objectives. 
Phase IV trials include additional drug-drug interaction(s), 
dose-response or safety studies and trials designed to 
support use under the approved indication(s), for example, 
mortality/morbidity studies, epidemiological studies etc’.
*In 1988, phase IV trials were not specifically mentioned in Schedule Y: the 1988 text above is a continuation of the 1988 Schedule Y text for 
phase III trials.
import for these purposes. New drugs, including FDCs, 
cease to be considered ‘new drugs’—and so no longer 
need CDSCO approval for marketing—4 years after their 
first approval. A duty on the regulator to be satisfied 
before approval that new drugs, including FDCs, are safe 
and effective was only imposed in 2001.15
Clinical trial requirements
Clinical trials must be carried out in India on ‘new drug 
substances discovered in India’ from phase I or from 
phase III if ‘discovered’ outside India. As shown in 
table 1, the 1988 rules specified the minimum numbers 
and ranges for trial participants and sites, but these were 
amended and downgraded in 2005.14
FdC data submission requirements
The data submission requirements for an FDC depend 
on which one of four FDC categories in Appendix VI 
of Schedule Y the FDC in question falls into: (1) one or 
more of the active ingredients is a new drug; (2) active 
ingredients already approved or marketed individually 
are combined for the first time; (3) already marketed 
but a change in active ingredient ratios is made; and (4) 
active ingredients concomitantly have been used for a 
particular indication for an extended period of time (a 
claim of convenience).14 These requirements and cate-
gories have been analysed previously, highlighting poor 
drafting and the downgrading of the rules in 2005.15
It is impossible to know what clinical evidence is before 
the regulator when it decides to approve an FDC for 
marketing for three reasons. First, although CDSCO 
publishes a list of FDCs that have been given marketing 
approval, no information is publicly available on which 
FDC category any particular approved FDC falls, and 
therefore the data submission requirements applying to 
a specific FDC are unknown.16 Second, CDSCO can over-
ride data submission requirements. It has a wide power 
to dispense with the requirement to submit data ‘if satis-
fied that there is adequate published evidence regarding 
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the safety of the drug’. In 2005, a further discretion was 
added, allowing toxicological and clinical data require-
ments to be ‘abbreviated, deferred or omitted’ if the drugs 
addressed ‘life threatening/serious diseases or diseases 
of special relevance to the Indian health scenario’. The 
Rules are silent on what constitutes the public interest, 
adequate published safety evidence and on what diseases 
are covered. The Rules do not require CDSCO to explain 
or make public its reasoning when exercising these 
discretions, and no public information is systematically 
made available as to whether they have exercised them. 
Third, the regulator does not publish or summarise the 
clinical evidence submitted to it or its evaluation of that 
evidence.
Guidance from CdSCo
There appears to be no finalised guidance on FDCs 
published by CDSCO.
Its website contains a draft document entitled ‘Guid-
ance for Industry on Fixed Dose Combinations’, dated 
April 2010, ‘for feedback purposes only. Comments and 
suggestions regarding this draft document should be 
submitted within 30 days of publication’.17 The document 
focuses on the forms and payments that drug companies 
must use and make and contain little substantive guid-
ance beyond reiterating the rules, and do not use the 
same FDC categories as those set out in Appendix VI of 
Schedule Y.14 The CDSCO website also contains a docu-
ment entitled ‘System of preliminary scrutiny by CDSCO 
at the time of receipt of application for approval of Fixed 
Dose Combinations’, which is stated to be effective from 
1 January 2011 but contains little substantive content.18
WHo guidelines
In 2005, the WHO adopted its guidelines for registration 
of fixed-dose medicinal products ‘intended to provide 
advice to those countries that do not, as yet, have guide-
lines for this type of product’ (see online supplementary 
figure 1).19 While India has had FDC-specific rules since 
1988, as well as draft industry guidance and a prelimi-
nary scrutiny document, the WHO guidelines are more 
extensive, substantive and clearly drafted. They contain a 
set of ‘general principles’ applying to clinical efficacy and 
safety evidence and assessment, which do not appear in 
the Indian Rules or administrative documents.
GATHeRInG THe ClInICAl TRIAlS evIdenCe
We previously reported PharmaTrac data of the five 
top-selling metformin FDCs in India for the 12-month 
period of November 2011 to October 2012.4 20 The 
following were the resulting five top-selling metformin 
FDCs: (1) glimepiride/metformin, (2) glimepiride/
pioglitazone/metformin, (3) glipizide/metformin, 
(4) glibenclamide/metformin, and (5) gliclazide/
metformin. Although all five of these top-selling formu-
lations were approved by CDSCO, three of these, 
glimepiride/metformin, glimepiride/pioglitazone/
metformin and gliclazide/metformin, were launched on 
the market prior to CDSCO approval (figure 1).4 PubMed 
and Embase databases and the Cochrane Library were 
searched from 1 January 1980 to 1 April 2016 for all 
published clinical trials on patients with type 2 diabetes 
investigating the five top-selling FDCs (see online supple-
mentary figures 2 and 3). After application of inclusion/
exclusion criteria, 25 publications remained eligible for 
inclusion: 3 of glimepiride/metformin, 2 of glimepiride/
pioglitazone/metformin, 1 of glipizide/metformin, 19 
of glibenclamide/metformin and none of gliclazide/
metformin (online supplementary figures 4 and 5 and 
tables 2, 3 and 4 illustrate the results of the search strategy 
for unpublished trials and detail the 16 retrieved unpub-
lished trials).
Overall, 23 of the 29 separate comparator arms (from 
25 trials) examined glibenclamide/metformin; three, 
glimepiride/metformin; two, glimepiride/pioglitazone/
metformin; one, glipizide/metformin; none, gliclazide/
metformin. In order to assist in the analysis, we grouped 
them into six categories of comparator arms: (1) FDC 
versus concomitant treatment with the FDC components 
given as SDFs; (2) FDC versus monotherapy with one of 
the components; (3) FDC versus a different FDC combi-
nation or concomitant SDF diabetes treatment; (4) FDC 
versus FDC with the same components but comparing 
different dosages or formulations (ie, dose 1 vs dose 2); 
(5) other (eg, same FDC in the same dosage/formu-
lation but under fed versus fasting conditions or no 
comparator); and (6) new FDC formulation versus previ-
ously marketed FDC (table 2). Only one trial compared 
an FDC (glibenclamide/metformin) versus concomitant 
treatment with glibenclamide and metformin.21 It was a 
2-week trial in 40 patients by an MNC, which evaluated 
glucose levels (not haemoglobin A1c (HbA1c)) but not 
adverse events. The trial was inadequately powered and 
was too short to support a robust evaluation of efficacy or 
safety of the FDC.
Only three clinical trials of metformin FDCs on patients 
with type 2 diabetes were conducted in India. One was a 
trial of 28 patients of 3-month duration and two other 
trials included 101 patients comparing the FDC glime-
piride/pioglitazone/metformin with metformin plus 
insulin or no treatment.22–24
WeIGHInG THe ClInICAl TRIAlS evIdenCe
Because CDSCO’s rules governing the approval of FDCs 
in India provide a great deal of latitude and have been 
weakened over time, we used the WHO’s 2005 Technical 
Report, Guidelines for Registration of Fixed-Dose Combina-
tion Medicinal Products, which was intended to provide 
guidance to drug regulatory agencies on robust registra-
tion requirements for FDCs given their growing use in 
treating diseases such as HIV, malaria and tuberculosis 
(see online supplementary figure 1).19 On the basis that 
diabetes is highly prevalent in India and affects millions 
of people, treatment is long term, and risks of hypogly-
caemia and poor tolerance are well-reported, we adopted 
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Table 2 Categories of comparator arms in 42 published and unpublished clinical trials of metformin FDCs in patients with 
type 2 diabetes.
Metformin FDC
Published/
Unpublished
Categories of comparator arms
FDC vs concomitant 
SDFs*
FDC vs 
monotherapy†
FDC vs 
other‡
FDC vs 
FDC§ Other¶
Experimental 
vs marketed**
Glimepiride
CDSCO approval 2002
Published 0 1 2 0 0 0
Unpublished 0 5 1†† 3†† 3 1
Glimepiride/Pioglitazone
CDSCO approval 2005
Published 0 0 1 0 1 0
Unpublished 0 0 3†† 2†† 0 0
Glipizide
CDSCO approval 1998
Published 0 1 0 0 0 0
Unpublished 0 0 0 0 0 0
Glibenclamide
CDSCO approval 1995
Published 1 8†† 6 7†† 0 1
Unpublished 0 1 1 0 0 0
Gliclazide
CDSCO approval 2005
Published 0 0 0 0 0 0
Unpublished 0 0 0 0 0 0
Online supplementary tables 3 and 4 provide details of the unpublished trials.
*FDC versus concomitant SDFs=FDC versus concomitant treatment with the FDC components given as SDFs.
†FDC versus monotherapy=FDC versus metformin and/or sulfonylurea monotherapy.
‡FDC versus other=FDC versus a different FDC combination or concomitant treatment.
§FDC versus FDC=same FDC components but comparing different dosages or formulations.
¶Other=same FDC but under different trial conditions, for example, fed versus fasting conditions.
**Experimental versus marketed=experimental (new) FDC versus previously marketed FDC.
††Trials (7) with multiple comparator arm categories in the same study.
CDSCO, Central Drugs Standard Control Organization; FDC, fixed-dose combinations; SDF, single-drug formulations. 
four criteria which we considered are generally necessary 
for evaluating the safety and efficacy evidence derived 
from clinical trials, relating to the size, duration, design 
and adverse reactions:
 ► Size: the WHO’s International Clinical Trials Registry 
Platform describes efficacy studies as being conduct-
ed in ‘large groups’ of people ‘from several hundred 
to several thousand’.
 ► Duration: the WHO guidelines state the minimum tri-
al duration, if the FDC is intended for long-term use, 
is 6 months.
 ► Design: the WHO guidelines ask whether the combi-
nation has an advantage over the individual compo-
nents.
 ► Adverse reactions: the WHO guidelines advocate the 
benefits should outweigh the potential adverse events.
We determined whether (1) there was a significant 
difference in the study outcome for the FDC over the 
comparator treatment, (2) the proportions of partici-
pants on the FDC experiencing adverse events or symp-
toms of hypoglycaemia were reported, (3) the study 
had balanced the advantages and disadvantages of the 
FDC over the comparator treatment, and (4) evidence 
and argument were presented to show that benefits 
outweighed potential adverse events.19 25
None of the 25 published clinical trials met all four 
selected WHO FDC criteria (table 3; see online supple-
mentary table 2). Table 3 shows each published trial 
against the WHO approval criteria for sample size, study 
duration, study design and that benefits should outweigh 
potential adverse events. For sample size, only 8 of the 25 
trials met our minimum number of subjects criterion of 
greater than 300 subjects and only 2 had more than 500 
subjects. Ten of the 25 trials met the minimum duration 
criterion of 6 months; only 4 were of 12-month duration. 
Of these only three met both the minimum number of 
subjects and minimum duration.26–28
Of the 25 trials, only one had been designed to show 
advantage over individual components. The single 
trial comparing the metformin/glibenclamide FDC 
with metformin and glibenclamide used concomitantly 
as SDFs among 40 patients over 2 weeks found lower 
2-hour postprandial glucose levels with the FDC, but 
the difference was not significant.21 Ten trials published 
data demonstrating each drug contributed to an overall 
advantage of the FDC over individual components by 
comparing the FDC with monotherapy. Of the remaining 
14 trials, 6 compared the FDC with another FDC, seven 
compared it with the same FDC at a different dosage or 
formulation, and one compared the FDC with a previ-
ously marketed FDC. To determine whether retrieved 
trials had presented a suitable argument for balancing 
the advantages and disadvantages of using an FDC over a 
standard oral hypoglycaemic treatment, we looked at the 
change in HbA1c versus the comparator arm, reported 
adverse events and incidents of hypoglycaemia to deter-
mine if an explanation of a balance of advantages and 
disadvantages was presented, and if a balance of harms 
and benefits of the experimental treatment was taken 
into account. Of the 25 trials, 14 reported a significant 
decrease in HbA1c levels with a metformin FDC versus 
monotherapy. Thirteen trials reported both frequency of 
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adverse events and symptoms of hypoglycaemia specifi-
cally for the FDC. Five studies reported adverse events 
or hypoglycaemia in aggregate but did not distinguish 
between treatment arms. Six studies did not report these 
outcomes and six studies only reported one of the two 
outcomes. In five trials more than 50% of participants 
experienced adverse events with FDCs; these were not 
statistically significant (or not reported) compared with 
the alternate treatment regimen(s). Three trials reported 
increased patient compliance as the explanation of 
benefit for the FDC over the comparator treatment.21 23 26 
However only one of these studies compared the FDC 
with concomitant treatment but did not report other 
supportive outcomes (ie, HbA1c levels, adverse events, 
hypoglycaemia).21 No studies balanced benefits and 
harms, that is, adverse reactions and clinical outcomes. 
Additional information on reported safety and efficacy 
for published trials is presented in online supplemen-
tary table 2. Overall, no trials provided enough evidence 
of safety and efficacy to justify the use of the FDC over 
concomitant treatments of the same active ingredients.
lACk oF ClInICAl TRIAl evIdenCe FoR meTFoRmIn FdCS In 
IndIA
None of the published trials included in this review met 
all four WHO-based criteria (table 3). Despite rigorous 
searching, we found only one study evaluating the effi-
cacy and safety of a metformin FDC versus concomitant 
use of the component drugs as SDFs; it was underpow-
ered and of poor quality.22 Most studies only compared 
metformin FDCs with monotherapies. Overall, more 
than half of the published trials were conducted in the 
USA, while only three were conducted in India. Only two 
trials were published prior to CDSCO approval (glime-
piride and glimepiride/pioglitazone), of which only 
one study was conducted on Indian patients prior to its 
launch in India.24 29 The Indian study evaluated the effi-
cacy of the FDC in just 101 patients with type 2 diabetes 
over 2 months of treatment.24
The overall lack of publicly available India-specific data 
heightens the need for publication of unpublished trials 
with Indian patients (see online supplementary table 
2). India has only required registration with CTRI, the 
national clinical trials database, since 2009. Although 
unpublished trials are listed in the clinical trial registries, 
they only provide basic trial information with no results 
or outcomes reported (see online supplementary table 
3). Both national and international databases of clinical 
trials should be updated routinely. The lack of trials on 
Indian patients, in particular, is of concern considering 
CDSCO’s guidelines for FDC approvals acknowledge the 
importance of conducting trials on the Indian popula-
tion to determine safety and efficacy.
The use of FDCs for treatment of diabetes has been 
described as an Indian innovation.30 Indeed, sales data 
show that hundreds of brands of metformin FDCs are 
on the market in India and outstrip sales of metformin 
SDFs in terms of both volume and value.4 20 India, there-
fore, should be at the forefront of regulatory practices. 
Although stringent pharmaceutical regulatory systems 
should be in place to protect patients from potentially 
dangerous medicines, as well as ensure the medicines are 
effective for the condition being treated, the recent over-
turning of the government ban on irrational FDCs raises 
serious questions about the strength of the rules on clin-
ical trials evidence. According to the WHO, FDCs that 
contain (1) the same active ingredients, (2) in the same 
doses, (3) as an established regimen of single drugs, (4) 
with the same dosage regimen, (5) a well-characterised 
efficacy and safety profile and (6) where the products 
used in obtaining clinical relevant outcomes have been 
shown to be of good quality need not ‘usually’ be trialled. 
However, given that none of the evaluated published 
trials provide such evidence, CDSCO should demon-
strate how it considers efficacy and safety to have been 
established. Although it is possible that CDSCO holds 
reliable evidence supporting metformin FDC approvals 
and knows the results of the unpublished trials, as is 
common with regulatory agencies, it should make the 
evidence and the trial results publicly available.
Our examination of published and unpublished studies 
of metformin FDCs for type 2 diabetes raises serious ques-
tions about the basis of CDSCO approvals as it shows the 
lack of trial evidence to support the efficacy and safety of 
the top-selling metformin FDCs approved for marketing, 
manufacture and sale in India. FDC treatments for 
diabetes are not recommended by national or interna-
tional treatment guidelines, yet many metformin FDCs 
have been approved by CDSCO. In addition, dozens of 
manufacturers have been licensed by individual States, 
but as public details of licences are not published we 
could not explore this further. The finding that three of 
the five top-selling metformin FDC formulations were 
launched on the market before CDSCO approval high-
lights weaknesses in the regulatory processes of both the 
federal system and the State regulators.
Furthermore, four out of five of these top-selling 
FDCs were found to be on the list of banned FDCs by 
the Ministry of Health and Family Welfare from March 
2016 (see online supplementary table 1).2 Hundreds of 
manufacturers, including many MNCs, petitioned State 
courts for a stay on the ban. In December 2016 they 
succeeded. The Delhi High Court ruled that CDSCO had 
not followed the appropriate procedures laid out in the 
Drugs and Cosmetics Act to impose the ban and reversed 
it, giving companies the ability to reintroduce potentially 
harmful medicines into the market-place.31 This ruling is 
currently headed to the Supreme Court.
MNCs have played a significant role in the clinical trials 
of metformin FDCs. Eighteen of the 25 published clinical 
trials conducted in patients with type 2 diabetes disclosed 
sponsor funding or were conducted by pharmaceutical 
companies. Eight different companies were represented 
as sponsors in the trials, with nine studies sponsored by 
MNCs. The poor quality of available published trials and 
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their funding sources raise concerns about the motiva-
tion for conducting these trials and whether the sponsors 
are using them for seeding or marketing purposes to gain 
a foothold in country markets.32
ConCluSIon
To our knowledge, this is the first study analysing the avail-
ability of published clinical trials evidence on the efficacy 
and safety of metformin FDCs. Our examination exposes 
serious deficiencies in the evidence base for metformin 
FDCs for type 2 diabetes and raises questions about the 
role of MNCs in manufacturing these for sale and use. To 
justify metformin FDC approvals and provide confidence 
in their efficacy and safety, CDSCO should make public 
the evidence it used in approving the metformin FDCs 
examined in this review. If that evidence does not extend 
beyond the trials reviewed here, those FDCs should be 
banned immediately. If that evidence includes the results 
of trials not reviewed in this paper, which do not meet 
the four WHO standards used for evaluation, those FDCs 
should be banned. Mitigation of any public health conse-
quences of removing widely used diabetes treatments 
from the market will require collaboration between the 
regulators, providers as well as drug manufacturers, 
to ensure that the medicines in the market-place have 
proven efficacy and safety. It is also necessary for clin-
ical trial databases to be constantly updated with both 
protocol and outcomes in order to improve transparency 
of trial data, and for the evidence underpinning drug 
approvals to be published. Legislation setting out clin-
ical trial requirements for new drugs should be revised to 
prevent irrational FDCs from entering the market. The 
government’s March 2016 ban on FDCs should be rein-
stated and a statutorily required review of FDCs estab-
lished, similar to the one mandated by the US Congress 
in 1962.
Acknowledgements The authors wish to thank Patricia McGettigan and Petra 
Sevcikova for critical review of the manuscript.
Contributors AMP conceived the study. PR contributed to the portion of the 
manuscript regarding regulation. VE conducted the literature search and data 
extraction, and drafted the manuscript. All authors contributed to the review of the 
manuscript and approval of the final submission.
Funding This report results from a research funded by the European Union 
Seventh Framework Programme Theme: Health 4200944.3.242 (grant no 242 
262) under the title Access to Medicines in Africa and South Asia (AMASA). The 
project team includes partners at the Swiss Tropical and Public Health Institute 
at the University of Basel (Switzerland), University of Edinburgh (UK), Queen Mary 
University of London (UK), University of Ghent (Belgium), Makerere University 
(Uganda), Mbarara University of Science and Technology (Uganda), University of the 
Western Cape (South Africa), and the Foundation for Research in Community Health 
(India). 
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. U.S. Food and Drug Administation. Novel drug approvals. htt p:// 
www. fda. gov/ Drugs/ DevelopmentApprovalProcess/ Drug Inno vati on/ 
de fault. htm (accessed 08 Jul 2016).
 2. Ministry of Health and Family Welfare, Department of Health and 
Family Welfare. Gazette of India, 10 March 2016. New Delhi, 2016. 
http://www. cdsco. nic. in/ writereaddata/ GSR705E. pdf (accessed 08 
Jul 2016).
 3. McGettigan P, Mahajan R, Kadam A, et al. Regulatory upheaval 
and irrational medicines in India: a study of fixed dose combination 
drugs. PLoS Med 2015;12:e1001826.
 4. Evans V, Pollock AM. The proliferation of irrational metformin 
fixed-dose combinations in India. Lancet Diabetes Endocrinol 
2015;3:98–100.
 5. Economic Times. 26 new drugs permitted for sale without trials in 
India. 18 August 2013. http:// articles. economictimes. indiatimes. 
com/ 2013- 08- 18/ news/ 41422720_ 1_ clinical- trials- drug- trials- drugs- 
standard- control- organisation (accessed 08 Jul 2016).
 6. Times of India. India is the diabetes capital of the world. 28 January 
2016. http:// timesofindia. indiatimes. com/ life- style/ health- fitness/ 
health- news/ India- is- the- diabetes- capital- of- the- world/ articleshow/ 
50753461. cms. (accessed 08 Jul 2016).
 7. Delhi High Court. W.P.(C) No.2212/2016. Date of Decision: 01 
December 2016. http ://l obis .nic.in/dd ir/ dhc /RSE/ judg emen t/01 -12- 
2016/ RSE01 1220 16C W22122016. pdf (accessed 06 Feb 2016).
 8. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination 
drugs on adherence to prescription medications. J Gen Intern Med 
2008;23:611–4.
 9. Schernthaner G. Fixed-dose combination therapies in the 
management of hyperglycaemia in Type 2 diabetes: an opportunity 
to improve adherence and patient care. Diabet Med 2010;27:739–43.
 10. Vittorino Gaddi A, Benedetto D, Capello F, et al. Oral antidiabetic 
therapy in a large Italian sample: drug supply and compliance for 
different therapeutic regimens. Public Health 2014;128:70–6.
 11. Cheong C, Barner JC, Lawson KA, et al. Patient adherence and 
reimbursement amount for antidiabetic fixed-dose combination 
products compared with dual therapy among Texas Medicaid 
recipients. Clin Ther 2008;30:1893–907.
 12. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with 
anti-hyperglycemic therapy: evaluation of a population of type 2 
diabetic patients. J Int Med Res 2002;30:71–9.
 13. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral 
antidiabetic therapy in a managed care organization: a comparison 
of monotherapy, combination therapy, and fixed-dose combination 
therapy. Clin Ther 2002;24:460–7.
 14. Central Drugs Standard Control Organization. Drugs and Cosmetics 
Rules 1945, Schedule Y. http:// cdsco. nic. in/ html/ D& C_ Rules_ 
Schedule_ Y. pdf (accessed 02 Jun 2017).
 15. Roderick P, Mahajan R, McGettigan P, et al. India should introduce a 
new Drugs Act. Lancet 2014;383:203–6.
 16. Central Drugs Standard Control Organization. Fixed Dose 
Combinations Approved by DCG(I) Since 1961 till 30th June 2017. 
http:// cdsco. nic. in/ writereaddata/ latesapproved% 20FDC% 20list% 
20till% 2030% 20june% 202017. pdf (accessed 11 Jul 2017).
 17. Central Drugs Standard Control Organization. Guidance for Industry 
on Fixed Dose Combinations (FDCs), April 2010. http://www. cdsco. 
nic. in/ writereaddata/ FDC% 20Guidelines% 20_% 20Revised1. pdf 
(accessed 11 Jul 2017).
 18. Central Drugs Standard Control Organization. System of preliminary 
scrutiny by CDSCO at the time or receipt of application for approval 
of Fixed Dose Combinations (FDCs). http://www. cdsco. nic. in/ 
writereaddata/ Fixed% 20dose% 20Combin. pdf (accessed 11 Jul 
2017).
 19. World Health Organization. Guidelines for registration of fixed-dose 
combination medicinal products - Annex 5. WHO Technical Report 
Series, No. 929. Geneva: World Health Organization, 2005.
 20. PharmaTrac. Sales and volume data, 2012..
 21. Donahue SR, Turner KC, Patel S. Pharmacokinetics and 
pharmacodynamics of glyburide/metformin tablets (Glucovance) 
versus equivalent doses of glyburide and metformin in patients with 
type 2 diabetes. Clin Pharmacokinet 2002;41:1301–9.
 22. Shimpi RD, Patil PH, Kuchake VG, et al. Comparison of effect of 
metformin in combination with glimepiride and glibenclamide on 
Evans V, et al. BMJ Glob Health 2018;0:e000263. doi:10.1136/bmjgh-2016-000263 11
BMJ Global Health
glycaemic control in patient with Type 2 diabetes mellitus. Int J 
PharmTech Res 2009;1:50–61.
 23. Bell DS, Dharmalingam M, Kumar S, et al. Triple oral fixed-
dose diabetes polypill versus insulin plus metformin efficacy 
demonstration study in the treatment of advanced type 2 diabetes 
(TrIED study-II). Diabetes Obes Metab 2011;13:800–5.
 24. Meshram DM, Langade DG, Kinagi SB, et al. Evaluation of 
efficacy and safety of fixed dose combination of glimepiride 2 
mg pluspioglitazone 15 mg plus metformin SR 500 mg in the 
management of patients with type-2 diabetes mellitus. J Indian Med 
Assoc 2005;103:447–50.
 25. World Health Organization. International Clinical Trials Registry 
Platform (ICTRP) - Glossary. Geneva: World Health Organization, 
2013. http://www. who. int/ ictrp/ glossary/ en/. (accessed 08 Jul 
2016).
 26. Blonde L, Joyal S, Henry D, et al. Durable efficacy of metformin/
glibenclamide combination tablets (Glucovance) during 52 weeks of 
open-label treatment in type 2 diabetic patients with hyperglycaemia 
despite previous sulphonylurea monotherapy. Int J Clin Pract 
2004;58:820–6.
 27. Dailey GE, Noor MA, Park JS, et al. Glycemic control with glyburide/
metformin tablets in combination with rosiglitazone in patients 
with type 2 diabetes: a randomized, double-blind trial. Am J Med 
2004;116:223–9.
 28. Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus 
metformin plus rosiglitazone in patients with type 2 diabetes 
inadequately controlled on metformin monotherapy. Diabetes Obes 
Metab 2006;8:156–63.
 29. Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control 
by addition of glimepiride to metformin monotherapy in type 2 
diabetic patients. Diabet Med 2001;18:828–34.
 30. Kalra S, Sahay BK, Rao MS. Fixed dose combinations in diabetes: 
Indian innovation, Indian pride. Indian J Endocrinol Metab 
2012;16(Suppl1):4–5.
 31. The Hindu. Delhi High Court reverses ban on combination drugs. 
01 December 2016. http://www. thehindu. com/ news/ national/ 
article16735149. ece
 32. Kessler DA, Rose JL, Temple RJ, et al. Therapeutic-class wars-
-drug promotion in a competitive marketplace. N Engl J Med 
1994;331:1350–3.
 33. González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. 
Efficacy of glimepiride/metformin combination versus glibenclamide/
metformin in patients with uncontrolled type 2 diabetes mellitus.  
J Diabetes Complications 2009;23:376–9.
 34. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-
masked, parallel-group assessment of simultaneous glipizide/
metformin as second-line pharmacologic treatment for patients 
with type 2 diabetes mellitus that is inadequately controlled by a 
sulfonylurea. Clin Ther 2003;25:890–903.
 35. Blonde L, Rosenstock J, Mooradian AD, et al. Glyburide/metformin 
combination product is safe and efficacious in patients with type 
2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 
2002;4:368–75.
 36. Bruce S, Park JS, Fiedorek FT, et al. Beta-cell response to 
metformin-glibenclamide combination tablets (Glucovance) in 
patients with type 2 diabetes. Int J Clin Pract 2006;60:783–90.
 37. Brunetti P, Pagano G, Turco C, et al. Effects of two different 
glibenclamide dose-strengths in the fixed combination with 
metformin in patients with poorly controlled T2DM: a double blind, 
prospective, randomised, cross-over clinical trial. Diabetes Nutr 
Metab 2004;17:350–7.
 38. Chien HH, Chang CT, Chu NF, et al. Effect of glyburide-metformin 
combination tablet in patients with type 2 diabetes. J Chin Med 
Assoc 2007;70:473–80.
 39. Comaschi M, Demicheli A, Di Pietro C, et al. Effects of pioglitazone 
in combination with metformin or a sulfonylurea compared to a 
fixed-dose combination of metformin and glibenclamide in patients 
with type 2 diabetes. Diabetes Technol Ther 2007;9:387–98.
 40. Comaschi M, Corsi A, Di Pietro C, et al. The effect of pioglitazone 
as add-on therapy to metformin or sulphonylurea compared to a 
fixed-dose combination of metformin and glibenclamide on diabetic 
dyslipidaemia. Nutr Metab Cardiovasc Dis 2008;18:373–9.
 41. Erle G, Lovise S, Stocchiero C, et al. A comparison of 
preconstituted, fixed combinations of low-dose glyburide plus 
metformin versus high-dose glyburide alone in the treatment of type 
2 diabetic patients. Acta Diabetol 1999;36:61–5.
 42. Flores-Murrieta FJ, Aguilar-Cota ME, Camacho A, et al. Comparative 
bioavailability of two oral formulations manufactured in Mexico 
containing glyburide and metformin in diabetic patients. Proc West 
Pharmacol Soc 2003;46:82–4.
 43. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/
metformin therapy is superior to component monotherapy as an 
initial pharmacological treatment for type 2 diabetes. Diabetes Obes 
Metab 2002;4:201–8.
 44. Garber AJ, Donovan DS, Dandona P, et al. Efficacy of glyburide/
metformin tablets compared with initial monotherapy in type 2 
diabetes. J Clin Endocrinol Metab 2003;88:3598–604.
 45. Marre M, Howlett H, Lehert P, et al. Improved glycaemic control with 
metformin-glibenclamide combined tablet therapy (Glucovance) 
in Type 2 diabetic patients inadequately controlled on metformin. 
Diabet Med 2002;19:673–80.
 46. Medina Santillán R, Reyes-García G, Mateos-García E. Metformin 
plus glyburide combination as therapy in failure to monotherapy in 
type 2 diabetic patients: one month follow-up. Proc West Pharmacol 
Soc 2002;45:139–40.
 47. Raptis AE, Tountas NB, Yalouris AG, et al. Therapeutic effect of 
glibenclamide in a fixed combination with metformin or phenformin 
in NIDDM patients. Horm Metab Res 1996;28:89–94.
 48. Tosi F, Muggeo M, Brun E, et al. Combination treatment with 
metformin and glibenclamide versus single-drug therapies in type 2 
diabetes mellitus: a randomized, double-blind, comparative study. 
Metabolism 2003;52:862–7.
